ADVERTISEMENT

Alembic Pharma Q4 Review: Dolat Capital Upgrades Rating To 'Add', Hikes Target Price Post Inline Results

Given the recent correction in Alembic Pharma's stock price there is a decent upside, hence Dolat Capital upgrades rating to ‘Accumulate’ from Reduce

Dolat Capital

07 May 2025, 08:53 AM IST i

<div class="paragraphs"><p>Alembic Pharma’s Q4FY25 sales and PAT were in line while Ebitda margin was slightly below estimates due to lower-than-expected gross margin and higher R&D costs offset by lower other expenses & staff costs.  </p><p> (Image Source: Freepik)</p></div>

Alembic Pharma’s Q4FY25 sales and PAT were in line while Ebitda margin was slightly below estimates due to lower-than-expected gross margin and higher R&D costs offset by lower other expenses & staff costs.

(Image Source: Freepik)

Alembic Pharma’s Q4 FY25 sales and PAT were in line while Ebitda margin was slightly below estimates due to lower-than-expected gross margin and higher research and development costs offset by lower other expenses and staff costs. US growth guidance of mid-teens likely to be driven by 15+ product launches and R&D guidance to be around Rs 6-6.5 billion in FY26.

OUR NEWSLETTERS

Sign Up

By signing up you agree to the Terms & Conditions of NDTV Profit